Listen in on the proceedings from RWCS with excerpts from leading teachers in rheumatology. This podcast features Drs. Bevra Hahn, Artie Kavanaugh and Anne Stevens. 

The 11th annual meeting of the Rheumatology Winter Clinical Symposium (RWCS) begins today (2/7) and runs through Saturday (2/10) and features a premiere faculty delivering state-of-the-art lectures.

Abatacept (Orencia) may be a useful treatment option for patients with rheumatoid arthritis (RA) who develop interstitial lung disease (ILD), a Spanish study suggested.

Biosimilars command a great deal of research, development and attention given the promise of significant cost savings and potentially wider use for those in need.  The global biosimilar market is expected to reach $36 billion USD by 2022. Here is this month's roundup of clinical trials and journal articles, overviews/reviews, practice and physician attitudes, and regulatory and pharma news - all on the subject of biosimilars.

Here are the 10 most talked about MMWR Reports of 2017. 

Methotrexate may provide benefits in treatment of the chronic arthritis that can persist following acute chikungunya virus infection, but definitive evidence remains lacking, researchers reported.

Dr. Jack Cush reviews highlights, news and recent research published this week on RheumNow.com. This week's report includes rising epidemiologic numbers, vaccine updates for H.

A prospective study has shown that ankylosing spondylitis (AS) patients often require narcotic analgesics to manage pain unresponsive to antiinflammatory therapies.

EUSTAR study results published in Arthritis Research & Therapy show the current state of immunosuppressive use in systemic sclerosis patients with interstitial lung disease (SSc-ILD) to be ill-defined, but that liberal use of glucocorticoids (GC) in SSc-ILD should be discouraged

Dr. David Daikh, president of the American College of Rheumatology (ACR) has written a letter to the Department of Health and Human Services (HHS) in response to their Request for Information on Promoting Health Care Choice and Competition Across the United States.  

In the past 2 decades, mortality from end-stage renal disease (ESRD) among U.S. patients with granulomatosis with polyangiitis (GPA) has declined significantly, a nationwide study found.

A claims data analysis shows that abatacept use in rheumatoid arthritis (RA) patients yielded a modestly reduced cardiovascular risk when compared to patients receiving TNF inhibitors (TNFi).

New data shows that nearly 15 percent of adult ibuprofen users exceed the maximum recommended dose of ibuprofen or other NSAIDs in a one-week period. 

Corticosteroid therapy is integral to the treatment of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) and a new retrospective cohort study from the UK shows that PMR and GCA have similar, increased risk of fractures.

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report covers the price of biologics treatment in psoriasis, comorbidities in myositis, bronchiectasis with MPO antibodies, and the risk of secondary TNF failure with anti-drug antibodies.

Like their adult counterparts, psoriasis in children is an independent risk factor for comorbidity, but not as much as  obesity.

An observational study of patients with active rheumatoid arthritis (RA) or spondyloarthritis (SpA) experiencing secondary failure to TNF inhibitor (TNFi) therapy showed that (secondary) loss of efficacy to a TNFi was associated with anti-drug antibodies in less than 30% of patients. 

Rheumatoid arthritis patients who were younger and who had lower body mass index, Health Assessment Questionnaire (HAQ) scores, and less disease activity at baseline were most likely to achieve remission after combination etanercept (Enbrel) and methotrexate induction therapy, a post hoc analysis of the PRESERVE trial found.

Lancet reports that in a study teriparatide with risedronate, post-menopausal women with severe osteoporosis had significantly fewer new vertebral and clinical fractures on teriparatide comared to those receiving risedronate.

The RAPID-axSpA study of ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) patients showed that certolizumab pegol (CZP) treatment yielded rapid clinical improvement with limited radiographic progression and MRI inflammation at the sacroiliiac (SI) joint over 4 years.